Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Bladder Cancer

Free Subscription 01.12.2025 1 Adv Sci (Weinh) 1 Antioxidants (Basel) 1 ArXiv 1 Biochem Pharmacol 1 Biology (Basel) 1 Biomark Med 1 BJU Int 1 BMC Cancer 1 BMC Urol 1 BMC Vet Res 2 BMJ Case Rep 1 BMJ Open 1 Cancers (Basel) 1 Cell Death Dis 8 Clin Genitourin Cancer 1 Clinics (Sao Paulo) 1 Crit Rev Oncol Hematol 1 Digit Health 1 Discov Oncol 1 Dose Response 1 Eur Urol Oncol 1 Eur Urol Open Sci 1 Expert Opin Drug Saf 1 Fr J Urol 1 Front Immunol 1 Future Cardiol 1 Gene 2 Hereditas 1 Indian J Surg Oncol 1 Int J Biol Sci 1 Int J Surg 1 J Biochem Mol Toxicol 1 J Chemother 1 J Clin Biochem Nutr 1 J Clin Med 1 J Exp Clin Cancer Res 1 J Immunother Cancer 1 J Microbiol 1 J Nanobiotechnology 1 J Transl Med 1 J Urol 1 Medicina (Kaunas) 1 Medicine (Baltimore) 1 medRxiv 1 Mutat Res 1 NPJ Precis Oncol 1 Pathologie (Heidelb) 1 Per Med 5 Sci Rep 1 Urol Oncol 1 World J Urol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Adv Sci (Weinh)

1. TU S, Du W, Luo Y, Shi J, et al
   YKT6 Promotes Bladder Cancer Progression by Stabilizing beta-catenin Through USP7-Mediated Deubiquitination.
   Adv Sci (Weinh). 2025 Nov 26:e07166. doi: 10.1002/advs.202507166.
   PubMed         Abstract available
   
   

   
   Antioxidants (Basel)

2. CIUMMO V, Ciafarone A, Altamura S, Lombardi F, et al
   Exploring the Anticancer Potential of the Multistrain Probiotic Formulation OxxySlab in Bladder Cancer Cell Lines.
   Antioxidants (Basel). 2025;14:1282.
   PubMed         Abstract available
   
   

   
   ArXiv

3. OLUMOYIN K, Rejniak K
   Modeling Adoptive Cell Therapy in Bladder Cancer from Sparse Biological Data using PINNs.
   ArXiv [Preprint]. 2025 Oct 15:arXiv:2510.13431.
   PubMed         Abstract available
   
   

   
   Biochem Pharmacol

4. TANG S, Liu Y, Jin B, Zhang T, et al
   LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1.
   Biochem Pharmacol. 2025;243.
   PubMed         Abstract available
   
   

   
   Biology (Basel)

5. ZHANG W, Zhou K, Chen P, Du X, et al
   Phase Separation Competent TIA1 Couples Glycolytic Shutdown to CD8(+) T-Cell Activation and Shapes the Efficacy of Intravesical BCG in Bladder Cancer.
   Biology (Basel). 2025;14:1576.
   PubMed         Abstract available
   
   

   
   Biomark Med

6. JIN T, Liu H, Li S, Chen H, et al
   A CT-based deep learning radiomics model for predicting HER2 expression and prognosis in non-muscle-invasive bladder cancer.
   Biomark Med. 2025 Nov 23:1-10. doi: 10.1080/17520363.2025.2590778.
   PubMed         Abstract available
   
   

   
   BJU Int

7. 
   Correction to "Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer".
   BJU Int. 2025 Nov 24. doi: 10.1111/bju.70090.
   PubMed        
   
   

   
   BMC Cancer

8. ZHAO Y, Li P, Shen Z, Yao S, et al
   Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence.
   BMC Cancer. 2025;25:1796.
   PubMed         Abstract available
   
   

   
   BMC Urol

9. YAMAZAWA A, Tsuchiya M, Imai S, Ikegami K, et al
   Survey of perioperative treatment in muscle-invasive bladder cancer using Japanese hospital-based claims database.
   BMC Urol. 2025 Nov 24. doi: 10.1186/s12894-025-01995.
   PubMed        
   
   

   
   BMC Vet Res

10. MUSCATELLO LV, D'Annunzio G, Franceschini T, Tugnoli C, et al
    Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma.
    BMC Vet Res. 2025;21:681.
    PubMed         Abstract available
    
    

    
    BMJ Case Rep

11. CAI C, Mancini J, Zhang S, Heymann J, et al
    Intravesical BCG for bladder cancer treatment complicated by disseminated BCG (BCGosis) with pericardial effusion and tamponade.
    BMJ Case Rep. 2025;18:e268921.
    PubMed         Abstract available
    
    
12. CHAN AW, Chiccarine A, Saxena S, Choi JW, et al
    Pan-urethral condyloma acuminatum in a bladder cancer patient.
    BMJ Case Rep. 2025;18:e269439.
    PubMed         Abstract available
    
    

    
    BMJ Open

13. FANG CW, Shau WY, Fan SZ, Chueh JS, et al
    Comparison of spinal versus general anaesthesia in high-risk non-muscle invasive bladder cancer: study protocol for a randomised controlled trial.
    BMJ Open. 2025;15:e107824.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

14. PINTON P
    Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions.
    Cancers (Basel). 2025;17:3631.
    PubMed         Abstract available
    
    

    
    Cell Death Dis

15. MAKABE S, Hoshi K, Kaneko H, Masuishi Y, et al
    MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells.
    Cell Death Dis. 2025;16:868.
    PubMed         Abstract available
    
    

    
    Clin Genitourin Cancer

16. OH E, Chua Y, Bahar P, Accardo ML, et al
    Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma.
    Clin Genitourin Cancer. 2025;23:102451.
    PubMed         Abstract available
    
    
17. JAIN P, Naqvi SAA, Tripathi N, Oberoi JK, et al
    Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis.
    Clin Genitourin Cancer. 2025;23:102453.
    PubMed         Abstract available
    
    
18. CHE G, Zhao X, Luo R, Yu Q, et al
    Macrophage Cell and Diagnostic Biomarkers in BLCA: Integrating Machine Learning With Single-Cell Analysis.
    Clin Genitourin Cancer. 2025;23:102447.
    PubMed         Abstract available
    
    
19. STEIDLE M, Malshy K, Hunt TC, Cheng Z, et al
    Study Endpoint Fulfillment and FDA Approval Success in Phase III Clinical Trials of Genitourinary Malignancies.
    Clin Genitourin Cancer. 2025;23:102436.
    PubMed         Abstract available
    
    
20. DE ANGELIS M, Siech C, Jannello LMI, Di Bello F, et al
    Rates of Secondary Bladder and Rectal Cancers After External Beam Radiation for Prostate Cancer According to Age and D'amico Risk Groups in A Contemporary Cohort.
    Clin Genitourin Cancer. 2025;23:102429.
    PubMed         Abstract available
    
    
21. ROBESTI D, Micheli F, Rai SN, Fallara G, et al
    Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation.
    Clin Genitourin Cancer. 2025;23:102423.
    PubMed         Abstract available
    
    
22. HOF JP, Kiemeney LALM, Aben KKH, van der Heijden AG, et al
    Recurrence Patterns in a Large Contemporary Cohort of Patients With Non-Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2025;24:102464.
    PubMed         Abstract available
    
    
23. CHOW RD, Mamtani R
    Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma.
    Clin Genitourin Cancer. 2025;23:102417.
    PubMed         Abstract available
    
    

    
    Clinics (Sao Paulo)

24. GALLUCCI FP, de Camargo JA, Viana NI, Pimenta RCA, et al
    CRISPR/Cas9-mediated MMP-9 silencing inhibits bladder cancer T24 cell invasion and migration in vitro.
    Clinics (Sao Paulo). 2025;80:100842.
    PubMed         Abstract available
    
    

    
    Crit Rev Oncol Hematol

25. ANSAB M, Rath S, Ishaque G, Araib E, et al
    Survival outcomes with enfortumab vedotin-containing regimens in metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Crit Rev Oncol Hematol. 2025;216:104945.
    PubMed         Abstract available
    
    

    
    Digit Health

26. PAN X, Wen L, Li Y, Zhang Y, et al
    LLM-BCgrading: Large language model-based Chinese medical long text classification for bladder cancer grade prediction.
    Digit Health. 2025;11:20552076251393290.
    PubMed         Abstract available
    
    

    
    Discov Oncol

27. BI C, Li K, Yang Y, Shi Y, et al
    Identification of potential bladder cancer drug targets through Mendelian randomization and molecular docking.
    Discov Oncol. 2025;16:2172.
    PubMed         Abstract available
    
    

    
    Dose Response

28. LI C, Lv G, Yue Y, Ma G, et al
    Piperine Targets the FANCL/UBE2T Complex to Inhibit the FA Pathway and Sensitize Bladder Cancer to Cisplatin.
    Dose Response. 2025;23:15593258251404060.
    PubMed         Abstract available
    
    

    
    Eur Urol Oncol

29. MARIAPPAN P, Hart-Brooke J, Sparks R, Lord-McKenzie T, et al
    Bladder EpiCheck triggered Photodynamic Diagnosis biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy.
    Eur Urol Oncol. 2025 Nov 27:S2588-9311(25)00295.
    PubMed         Abstract available
    
    

    
    Eur Urol Open Sci

30. FINATI M, Schiavone N, Barone B, Contieri R, et al
    Refining Active Surveillance Eligibility in Intermediate-risk Non-muscle-invasive Bladder Cancer: The Impact of Time to First Recurrence.
    Eur Urol Open Sci. 2025;82:155-159.
    PubMed         Abstract available
    
    

    
    Expert Opin Drug Saf

31. XU B, Zhang T, He Y, Jiang A, et al
    Impact of sodium glucose cotransporter 2 inhibitors on bladder cancer and breast cancer: a pharmacovigilance analysis and Mendelian randomization study.
    Expert Opin Drug Saf. 2025 Nov 27:1-10. doi: 10.1080/14740338.2025.2595727.
    PubMed         Abstract available
    
    

    
    Fr J Urol

32. DOIZI S, Abid N, Traxer O, Panthier F, et al
    The role of lasers in the management of bladder tumors.
    Fr J Urol. 2025;35:102970.
    PubMed         Abstract available
    
    

    
    Front Immunol

33. BROCHIER W, Nguyen S, Cesson V, Bricard O, et al
    Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.
    Front Immunol. 2025;16:1627914.
    PubMed         Abstract available
    
    

    
    Future Cardiol

34. SCHOETTLER FI, Fatehi Hassanabad M, Webb NA, Clark J, et al
    Intraoperative urothelial carcinoma tumor thrombus embolization to the heart: a case report.
    Future Cardiol. 2025;21:879-881.
    PubMed         Abstract available
    
    

    
    Gene

35. FRASCOLLA C, Mastroianni R, Simone G, Blandino G, et al
    The role of 3D preclinical models in the Era of precision medicine: A bladder cancer perspective.
    Gene. 2025;979:149919.
    PubMed         Abstract available
    
    

    
    Hereditas

36. XIAOHUI Y, Jie L, Jiangqiao Z
    Coptisine regulates PI3K/AKT pathway to block bladder cancer progression: a study based on network pharmacology, in vitro and in vivo assays.
    Hereditas. 2025;162:232.
    PubMed         Abstract available
    
    
37. ZHU K, Zhang Z, Li T, Sun Y, et al
    Integrative multi-omics and single-cell transcriptomics reveal ARHGEF12 driving chemoresistance in bladder cancer.
    Hereditas. 2025;162:234.
    PubMed         Abstract available
    
    

    
    Indian J Surg Oncol

38. DASH NR, Mohapatra V, Madhusudan KS, Pal S, et al
    Role of Portal Vein Embolization Alone in Surgical Management of Locally Advanced Gall Bladder Cancer (PROVE-GBC): A Prospective Clinical Trial.
    Indian J Surg Oncol. 2025;16:1143-1151.
    PubMed         Abstract available
    
    

    
    Int J Biol Sci

39. XIONG S, Fan J, Huang C, He S, et al
    Single-cell and spatial transcriptomic analysis reveal cellular heterogeneity and cancer cell-intrinsic major histocompatibility complex II expression in urothelial carcinoma.
    Int J Biol Sci. 2025;21:6649-6673.
    PubMed         Abstract available
    
    

    
    Int J Surg

40. ZENG S, He W, Liu L, Ying Y, et al
    Chromosomal instability-guided urine sediment analysis enables non-invasive monitoring of minimal residual disease in bladder cancer.
    Int J Surg. 2025 Nov 10. doi: 10.1097/JS9.0000000000003865.
    PubMed        
    
    

    
    J Biochem Mol Toxicol

41. YUAN F, Li X, Hong C, Huang X, et al
    Synergistic Anticancer Effects of COL6A1 Downregulation and the PD1 Inhibitor Pembrolizumab in Bladder Cancer.
    J Biochem Mol Toxicol. 2025;39:e70621.
    PubMed         Abstract available
    
    

    
    J Chemother

42. HAN Y, Wang S, Xia R, Zhou B, et al
    USP54 suppresses bladder cancer proliferation, stemness, and cisplatin resistance via deubiquitination-mediated stabilization of SIRT6.
    J Chemother. 2025 Nov 26:1-13. doi: 10.1080/1120009X.2025.2591510.
    PubMed         Abstract available
    
    

    
    J Clin Biochem Nutr

43. MO Q, Lu Y, Wu J, Zhang X, et al
    DNA methylation of CA10 regulates the proliferation and metastasis of bladder cancer.
    J Clin Biochem Nutr. 2025;77:240-248.
    PubMed         Abstract available
    
    

    
    J Clin Med

44. GHOLAMI SS, Movassaghi M, Homayoun S, Vasdev N, et al
    Clinical Experience with URO17((R)) in the Diagnosis and Surveillance of Bladder Cancer.
    J Clin Med. 2025;14:8108.
    PubMed         Abstract available
    
    

    
    J Exp Clin Cancer Res

45. WANG T, Ma X, Wang Y, Liu H, et al
    Lactate-driven lactylation of HNRNPA1 orchestrates PKM2 splicing and glycolytic reprogramming in bladder cancer.
    J Exp Clin Cancer Res. 2025 Nov 22. doi: 10.1186/s13046-025-03591.
    PubMed         Abstract available
    
    

    
    J Immunother Cancer

46. CAI T, Feng T, Zhang W, Ge Q, et al
    Neutrophil extracellular traps-STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer.
    J Immunother Cancer. 2025;13:e012736.
    PubMed         Abstract available
    
    

    
    J Microbiol

47. TRAN TA, Lee HY, Choi HW
    Metabolite-mediated mechanisms linking the urinary microbiome to bladder cancer.
    J Microbiol. 2025;63:e2509001.
    PubMed         Abstract available
    
    

    
    J Nanobiotechnology

48. ZHANG Y, Yang E, Zhang X, Shi Y, et al
    A novel sono-activatable nanoreactor induces precision intratumoral juglone generation and caspase 3/GSDME-mediated pyroptosis for treatment of bladder cancer.
    J Nanobiotechnology. 2025 Nov 22. doi: 10.1186/s12951-025-03855.
    PubMed         Abstract available
    
    

    
    J Transl Med

49. TIAN H, Song J, Cong J, Zhang Z, et al
    Protein kinase D2-mediated maintenance complex component 2 phosphorylation promotes bladder cancer progression.
    J Transl Med. 2025;23:1357.
    PubMed         Abstract available
    
    

    
    J Urol

50. GONZALEZ-PADILLA DA, Subiela JD, Villacampa-Auba F
    Immune checkpoint inhibitors for high-risk non-muscle invasive bladder cancer: Lessons learnt from the CREST and POTOMAC trials.
    J Urol. 2025 Nov 25:101097JU0000000000004864. doi: 10.1097/JU.0000000000004864.
    PubMed        
    
    

    
    Medicina (Kaunas)

51. RATHORE V, Lin WW
    Decoding SIGLEC12 in Bladder Cancer: In Silico Profiling of Expression, Tumor-Immune Interactions, and Prognostic Impact.
    Medicina (Kaunas). 2025;61:1894.
    PubMed         Abstract available
    
    

    
    Medicine (Baltimore)

52. YANG J, Xu Z, Tao B, Zhao Y, et al
    Causal insights into immune cell profiles, plasma metabolites, and bladder cancer: A Mendelian randomization approach.
    Medicine (Baltimore). 2025;104:e46062.
    PubMed         Abstract available
    
    

    
    medRxiv

53. GREENBERG ZF, Hutchinson TE, Kahn J, Graim KS, et al
    Urinary extracellular vesicles for high-precision bladder cancer subtyping and prognosis.
    medRxiv [Preprint]. 2025 Oct 17:2025.10.14.25338041.
    PubMed         Abstract available
    
    

    
    Mutat Res

54. YUAN Q, Liu B, Yan W, Li H, et al
    FOXA2 promotes glutamine metabolism to facilitate the malignant development of bladder cancer by transcriptionally increasing GLS1 expression.
    Mutat Res. 2025;831:111920.
    PubMed         Abstract available
    
    

    
    NPJ Precis Oncol

55. SHEN J, Li Z, Wang R, Ding G, et al
    Bladder cancer diagnostic and prognostic models from DNA methylation by multi algorithm machine learning.
    NPJ Precis Oncol. 2025 Nov 26. doi: 10.1038/s41698-025-01195.
    PubMed         Abstract available
    
    

    
    Pathologie (Heidelb)

56. PANNHAUSEN J, Chughtai AA, Melzer MK, Ma Y, et al
    POLQ and DNA-PK inhibition in muscle-invasive bladder cancer : Enhancing radiosensitivity with novel DNA damage response inhibitors to improve radiotherapy outcomes.
    Pathologie (Heidelb). 2025 Nov 26. doi: 10.1007/s00292-025-01507.
    PubMed         Abstract available
    
    

    
    Per Med

57. JAIN A, Dey S, Garg D, Singh H, et al
    A multilevel ensemble model for predicting mutation types in bladder cancer.
    Per Med. 2025 Nov 26:1-10. doi: 10.1080/17410541.2025.2592530.
    PubMed         Abstract available
    
    

    
    Sci Rep

58. ALSAYEH AR, Abdelrazek EM, Oraby AH, Shokeir AA, et al
    Red single wavelength emitting up-conversion nanoparticles modulate cellular dynamics and gene expression in T24 bladder cancer cells.
    Sci Rep. 2025;15:42539.
    PubMed         Abstract available
    
    
59. KOBAYASHI T, Kitamura H, Furukawa Y, Shono M, et al
    JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.
    Sci Rep. 2025;15:41773.
    PubMed         Abstract available
    
    
60. KANESAKA M, Sazuka T, Kita Y, Fukuhara H, et al
    Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer.
    Sci Rep. 2025;15:41872.
    PubMed         Abstract available
    
    
61. LI M, Li Z, Xu C, Chen Y, et al
    Semi-supervised medical image segmentation of bladder tumors based on supervised branches and uncertainty estimation.
    Sci Rep. 2025;15:41517.
    PubMed         Abstract available
    
    
62. YU SY, Li HY, Wang CY, Wang WJ, et al
    Tumor-derived lactate fuels the STAT3-LCN2 pathway to promote bladder cancer malignancy and chemoresistance.
    Sci Rep. 2025;15:41610.
    PubMed         Abstract available
    
    

    
    Urol Oncol

63. FINOCCHIARO A, Contieri R, Piccolini A, Brin P, et al
    Assessing risk stratification in Bacillus Calmette-Guerin-treated high-grade Ta nonmuscle-invasive bladder cancer patients.
    Urol Oncol. 2025 Nov 27:S1078-1439(25)00447.
    PubMed         Abstract available
    
    

    
    World J Urol

64. SONG JJ, Zhou MT, Lee SZ, Jones JM, et al
    Safety of transurethral resection of bladder tumor in octogenarians: a NSQIP analysis.
    World J Urol. 2025;43:718.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.